Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

This is an open label extension of 306 subjects from a previously reported delayed-start phase III clinical trial of rasagiline in early Parkinson's disease. Clinical benefit observed at one year in the early vs. delayed-start arm was maintained over an average 3.6 ± 2.1 years observation, raising the question of whether earlier intervention with rasagiline results in better outcomes.

Is Earlier Treatment of Parkinson's Disease Better?